CD19 and neoplasm: B-lineage non-Hodgkin lymphoma (B-NHL) patients treated with anti-CD19 CAR-T therapy showed stronger response rates in those with higher baseline peripheral eosinophil counts, and eosinophil depletion reduced tumor infiltration by CAR-T cells and impeded their anti-tumor efficacy in a pre-clinical mouse lymphoma model [107].